Fulgent Genetics

Today at the ASCO 2026 Annual Meeting in Chicago, our team presented updated interim Phase 2 data on FID-007 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

The updated dataset showed an objective response rate of 61.9% and a manageable safety profile, with activity observed in both HPV-related and HPV-unrelated disease. A Phase 3 study is planned.

Thank you to the patients and families who participated in the study, the clinical investigators and sites who carried it out, our partners in oncology, and the Fulgent Pharma team.

We're grateful for the opportunity to share this work with the oncology community, and we look forward to continuing it.

Read the full release at https://ir.fulgentgenetics.com/news-releases/news-release-details/fulgent-presents-updated-fid-007-data-asco-2026. Presentation slides are available on Fulgent's investor relations page.

Fulgent is excited to exhibit at this year’s Festival of Genomics, Biodata & AI in Boston.

Fulgent can power your programs from Discovery through Development. We offer one of the largest portfolios of genetic tests in the industry (18,000+) and have integrated multiomic and pathology workflows. We operate CLIA/CAP-accredited labs across the US, Australia, and China. Our 6,700-gene CE-marked Clinical Exome panel rounds out our end-to-end offerings.

Whether you're exploring new testing capabilities, looking to improve your turnaround times, or just want to chat about genomics, we’d love to meet you!

📍 Booth #19 | June 3-4

We're excited to announce a significant expansion of Fulgent's cardiovascular test menu. The update spans cardiomyopathy, arrhythmia, lipid disorders, and more, with 99 newly added genes on our Comprehensive Cardiovascular NGS Panel (now 363 genes total) and a brand-new Comprehensive Dyslipidemia Panel.

A few of the updated panels:

🔶 Comprehensive Cardiovascular NGS Panel: 363 genes
🔶 Comprehensive Cardiomyopathy Panel: 172 genes
🔶 Long QT/Brugada Syndrome Panel: 36 genes
🔶 Comprehensive Dyslipidemia Panel: 34 genes (new)
🔶 Atrial Fibrillation Panel: 28 genes
🔶 Familial Hypercholesterolemia Panel: 10 genes

As with most Fulgent tests, each one can be tailored to a focused subset of genes to fit the clinical needs of individual patients.

Learn more at https://www.fulgentgenetics.com/products/disease/cardiovascular.html

Each year, roughly 73,000 people in the U.S. and 930,000 people worldwide are diagnosed with head and neck squamous cell carcinoma ( ). For more than half, the disease will recur or progress to a metastatic stage, where treatment options remain limited.

We're encouraged to share that the full abstract from our Phase 2 study of FID-007 in combination with cetuximab is now available on the ASCO 2026 website (https://www.asco.org/annual-meeting) as well as Fulgent’s IR site (https://ir.fulgentgenetics.com/news-events/presentations). Interim data show meaningful clinical activity in this hard-to-treat population, with an objective response rate of 60% and a favorable safety profile across both dosing arms.

Diagnostics and therapeutics are two sides of the same mission at Fulgent — developing flexible, affordable solutions that improve the everyday lives of those around us, and bringing us closer to a fully integrated precision medicine company. FID-007 is one piece of that work in oncology.

Read more at:
https://ir.fulgentgenetics.com/news-releases/news-release-details/fulgent-announces-rapid-oral-full-abstract-publication-fid-007

Updated presentation slides will be posted at the start of the rapid oral abstract session on June 1, 4:30pm to 6:00pm CDT, in Hall D1 of McCormick Place, Chicago.

Heading to in Chicago?

Fulgent will be exhibiting and connecting with teams advancing clinical oncology programs from translational research through trial ex*****on. We offer global support from the US, Australia, and China in CLIA-certified and CAP-accredited laboratories.

For groups building or scaling biomarker strategies, we support clinically relevant oncology workflows including:

• Solid tumor NGS molecular profiling (DNA+RNA) with key IO biomarkers like MSI and TMB
• Liquid biopsy / ctDNA profiling for solid tumors
• Heme NGS panels and specialized hematopathology testing
• HRR/HRD molecular profiling and germline hereditary cancer testing
• IHC/FISH and cytogenetics to complement NGS readout

Stop by booth #11094 or reach out to [email protected] beforehand to connect!

We Have Everything Under the Sea. 🌊

Catch Fulgent at 's Exhibit Fair & Strolling Dinner next Thursday, 5/28, from 6:00–9:00 PM in San Diego. This year's theme felt like a fit: across reproductive, oncology, rare disease, pharmacogenomics, and pathology, Fulgent covers the patient's full journey, all under one roof.

Come swap a story, grab a bite, and pick up some sea-creature swag.

May is Ehlers-Danlos Syndromes (EDS) and Hypermobility Spectrum Disorders (HSD) Awareness Month, and we're marking it with significant expansions to two of our connective tissue panels.

Ehlers-Danlos syndromes and related connective tissue disorders can present with a wide range of symptoms across multiple body systems, often overlapping with other conditions. Identifying the underlying genetic etiology can shift care toward more personalized treatment and symptom management.

Two panel updates to know about:

🔶 Ehlers-Danlos Syndrome (EDS) Panel: 17 new genes added, for a new total of 39. Includes genes associated with all 13 EDS types.

🔶 Comprehensive Connective Tissue Disease Panel (renamed and expanded from our previous Connective Tissue Disease Panel): 56 new genes added, for a new total of 119. Covers genes associated with Ehlers-Danlos syndrome, Loeys-Dietz syndrome, Stickler syndrome, Marfan syndrome, and thoracic aortic aneurysm and dissection.

For patients still searching for answers, these expanded panels offer a more comprehensive look at the genetic landscape behind connective tissue disorders.

We've added carefully curated genes to both of our infertility panels, broadening coverage for more clinical impact:

✓ Female Infertility Panel:
41 genes added, for a new total of 143 — now including all OZEMA (Oocyte/Zygote/Embryo Maturation Arrest) genes

✓ Male Infertility Panel:
17 genes added, for a new total of 163

Pairing infertility testing with offers an even more complete picture for patients navigating their reproductive journey. One partner, every step.

Learn more:
https://web.fulgentgenetics.com/resources/testing-with-fulgent/reproductive-health

The 1970's marked an increase in clinical lab usage that parallelled a shortage of lab technicians, which has remained an unfortunate trend to this day. In 2020, that shortage was keenly felt as the COVID pandemic caused a surge in lab testing. Lab workers are the all-too-often unsung heroes of healthcare.

So this , we'd like to express our gratitude to the Fulgent lab staff who work tirelessly behind the scenes on behalf of patients and the healthcare community. Thank you for all you do.

The latest findings on the efficacy of Fulgent's nano-encapsulated anti-tumor drug FID-007 will be presented at this year's American Society of Clinical Oncology (ASCO) meeting.

We're proud to announce that our abstract, “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)”, will be featured at the Head and Neck Cancer Track of the ASCO rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago.

The Phase 2 study is designed to evaluate the efficacy of different dosing regimens as well as to characterize the pharmacokinetics (PK) and safety and tolerability of FID-007 in combination with cetuximab in patients with disease progression after treatment with PD-L1-based immune checkpoint inhibitor.

https://www.businesswire.com/news/home/20260422182838/en/Fulgent-Selected-to-Present-Rapid-Oral-Abstract-Within-the-Head-and-Neck-Cancer-Track-Session-at-the-2026-ASCO-Annual-Meeting